Abstract: There are disclosed compounds of the formulaA(CH.sub.2).sub.n O--BwhereinA is ##STR1## n is 1-2; B is ##STR2## wherein R.sup.4 and R.sup.5 are each, independently, hydrogen or lower alkyl;R.sup.6 is hydrogen, halo or nitro; ##STR3## R.sup.8 is lower alkyl; m is 0-3;and the pharmacologically acceptable salts thereof, and their use in the treatment of inflammatory conditions, such as rheumatoid arthritis, ulcerative colitis, psoriasis and other immediate hypersensitivity reactions; in the treatment of leukotriene-mediated nasobronchial obstructive air-passageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like; and as gastric cytoprotective agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R is hydroxy, lower alkoxy or lower alkoxyamino;R.sup.1 is hydrogen or A(CH.sub.2).sub.n O--;R.sup.2 is hydrogen or A(CH.sub.2).sub.n O--, with the proviso that one of R.sup.1 and R.sup.2 is A(CH.sub.2).sub.n O-- and the other is hydrogen;n is 1-2;A is phenoxyethyl, phenoxyphenyl or a group having the formula ##STR2## X is --N-- or ##STR3## Z is ##STR4## R.sup.3 is hydrogen, lower alkyl or phenyl; R.sup.4 is hydrogen or lower alkyl; orR.sup.3 and R.sup.4 taken together form a benzene ring;R.sup.5 is hydrogen or lower alkyl;R.sup.

Abstract: There are disclosed compounds of the formula ##STR1## wherein A is alkyl of 3-19 carbon atoms, diloweralkyl allyl, dihaloallyl, diphenylallyl, lower alkynyl, ##STR2## X is N or CR; Z is ##STR3## R is hydrogen or lower alkyl; R.sup.1 is hydrogen, lower alkyl or phenyl;R.sup.2 is hydrogen or loweralkyl; orR.sup.1 and R.sup.2 taken together form a benzene ring;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

Abstract: There are disclosed compounds of the formula ##STR1## n is 0-5; R.sup.2 is, independently, hydrogen, loweralkyl, loweralkoxy, trifluoromethyl or halo; ##STR2## W represents a bond or ##STR3## m is 1-15; R.sup.4 is hydrogen or loweralkyl;R.sup.5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or ##STR4## or a pharmaceutically acceptable salt thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 is ##STR2## n is 0-5; R.sup.2 is hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo;R.sup.3 is hydrogen or loweralkyl;R.sup.4 hydrogen, lower alkyl, --COOR.sup.3 or ##STR3## R.sup.5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or ##STR4## and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein ##STR2## n is 0-5; R.sup.2 is hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo;R.sup.3 ##STR3## W represents a bond or --O--, --S-- or ##STR4## m is 1-15; R.sup.4 is hydrogen or loweralkyl;R.sup.5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or ##STR5## R.sup.6 is hydrogen, lower alkyl, --COOR.sup.4 or ##STR6## and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein X is N or CR.sup.1Y is O, S, NR.sup.1, CHR.sup.1 or C(R.sup.1).sub.2 when n=O, or N or CR.sup.1 when n=1;p is 0-3;R.sup.1 is hydrogen or lower alkyl;R.sup.2 is H, ##STR2## --SO.sub.2 R.sup.3 or --SO.sub.2 N(R.sup.3).sub.2, lower alkyl, lower alkenyl, lower alkynyl or lower alkyl carbonyl prolinate;R.sup.3 is H, lower alkyl or perfluoro lower alkyl;R.sup.4 is lower alkyl, phenyl, pyridyl or thienyl;R.sup.5 is hydrogen, lower alkyl, phenyl or pyridyl;A is O or NR.sup.1 ;B is OR.sup.1 or N(R.sup.5).sub.2 ;m is 0-2;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like.

Abstract: There are disclosed compounds of the formula ##STR1## wherein X is ##STR2## Y is ##STR3## Z is ##STR4## R.sup.1 is ##STR5## n is 0-5; R.sup.2 is hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo;R.sup.3 is ##STR6## W represents a bond or ##STR7## m is 1-15; R.sup.4 is hydrogen or loweralkyl;R.sup.5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or ##STR8## R.sup.6 is hydrogen, lower alkyl, ##STR9## and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein ##STR2## R.sup.2 is hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo;R.sup.3 is hydrogen or loweralkyl;R.sup.4 is hydrogen, lower alkyl, --COOR.sup.3 or ##STR3## R.sup.5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or ##STR4## and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein X is --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, ##STR2## Z is CR or N, where n=1; or Z is O,S, or NR, when n=0; R is hydrogen or loweralkyl;n is 0 or 1;R.sup.1 is hydroxy, amino, loweralkyl sulfonamido, perfluoro loweralkyl sulfonamido or OR;R.sup.2 is hydrogen or loweralkyl;R.sup.3 is hydrogen or loweralkyl; orR.sup.2 and R.sup.3 taken together form a benzene ring; andthe dotted line represents an optional double bond;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like.

Abstract: There are disclosed compounds having the formula ##STR1## wherein X is CR or N when n=1; orX is O, S, NR or CR when n=0;R is hydrogen or lower alkyl;Y is --CH.sub.2 --, --S--, --O-- or ##STR2## and A is ##STR3## Z is CH or N; R.sup.1 is halo or trifluoromethyl;R.sup.2 is hydrogen or halo;R.sup.3 is hydrogen or halo;with the proviso that when A is naphthyl, Y is --O-- and n=0, X is other than S; and their use in the treatment of inflammatory conditions and in the treatment of leukotriene-medicated naso-bronchial obstructive passageway conditions.

Abstract: There are disclosed compounds of the formula ##STR1## wherein X is --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, ##STR2## Z is CR or N, when n=1; or Z is O, S, or NR, when n=0, R is hydrogen or loweralkyl;n is 0 or 1;R.sup.1 is hydroxy, amino, loweralkyl sulfonamido, perfluoro loweralkyl sulfonamido or OR;R.sup.2 is hydrogen or loweralkyl;R.sup.3 is hydrogen or loweralkyl; orR.sup.2 and R.sup.3 taken together form a benzene ring; andthe dotted line represents an optional double bond;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like.

Abstract: There are disclosed compounds of the formula ##STR1## wherein X is ##STR2## W is --O--, --S--, ##STR3## when n=0, or W is ##STR4## when n=1, and the dotted line represents an optional double bond; Y is --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 S--, --SCH.sub.2 --, ##STR5## n is 0-1; R.sup.1 is hydrogen, loweralkyl, loweralkoxy, lower alkanoyl, halo, trifluoromethyl, cyano or nitro;R.sup.2 is hydrogen or loweralkyl;R.sup.3 is loweralkyl, perfluoroloweralkyl or perfluorophenyl, with the proviso that when X=N, W=O or S and n=0, R.sup.3 is other than loweralkyl;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and in antithrombotic therapy.

Abstract: There are disclosed compounds of the formula ##STR1## wherein X is --Ch.sub.2 CH.sub.2 --, --CH=CH--, ##STR2## Z is CR or N, when n=1; or Z is O, S, or NR, when n=0; R is hydrogen or loweralkyl;n is 0 or 1;R.sup.1 is hydroxy, amino, loweralkyl sulfonamido, perfluoro loweralkyl sulfonamido or OR;R.sup.2 is hydrogen or loweralkyl;R.sup.3 is hydrogen or loweralkyl; orR.sup.2 and R.sup.3 taken together form a benzene ring; andthe dotted line represents an optional double bond;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like.

Abstract: There are disclosed compounds of the formula ##STR1## wherein Z is CR or N, when n=1; or Z is O, S, or NR, when n=0; n is 0 or 1; p is 1-10; R.sup.1 is hydrogen, loweralkyl, loweralkoxy or halo; R.sup.2 is hydrogen, loweralkyl, loweralkoxy or halo; or R.sup.1 and R.sup.2 taken together form a benzene ring; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like.

Abstract: The compounds ##STR1## wherein each X is, independently, --O-- or --NR.sub.5, in which R.sub.5 is hydrogen or alkyl; R is alkyl, R.sub.1 is hydrogen or alkyl, R.sub.2 is hydrogen, hydroxy, amino, alkylamino, dialkylamino or alkanoylamino and when m or n is O, R.sub.2 is hydroxymethyl, aminomethyl, alkylaminomethyl, dialkylaminomethyl or alkanoylaminomethyl; R.sub.3 is hydrogen, --CN, --CONH.sub.2 or --CO.sub.2 M in which M is hydrogen, alkyl or ##STR2## in which p is an integer from 2 to 6 and R.sub.6 and R.sub.7 are, independently, hydrogen or alkyl; R.sub.4 is --NH.sub.2, --NHCOR.sub.8 in which R.sub.8 is alkyl, --NHCOCO.sub.2 Z or --NHCOCH.sub.2 CH.sub.2 CO.sub.2 Z in which Z is hydrogen or alkyl; m and n are 0, 1, 2, 3 or 4 such that when n is from 1 to 4, m is 0 or 1 and when m is from 1 to 4, n is 0 or 1; or pharmaceutically acceptable salts thereof are leucotriene antagonists useful as antiallergy agents.